EMD 57033: A novel Ca2+ sensitizing agent

Cardiovascular Drug Reviews

Volumn 14, Issue 4, 1996, Pages 334-350

  Schipke, J D ^a   Korbmacher, B ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Ca2+ sensitizer; Calcium; Cardiac stimulants; EMD 53988; EMD 57033; Heart failure; Myocardium; Thiadiazinone

Indexed keywords

5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ACTIN; ADENOSINE TRIPHOSPHATASE; CALCIUM SENSITIZER; CARDIOTONIC AGENT; CYCLIC AMP; HEART ENZYME; INOTROPIC AGENT; PHOSPHODIESTERASE; PIMOBENDAN; TROPONIN C;

ACIDOSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; DIASTOLE; DRUG EFFICACY; DRUG STRUCTURE; ENERGY EXPENDITURE; ENZYME ACTIVITY; EXCITATION CONTRACTION COUPLING; HEART CONTRACTION; HEART DISEASE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; HUMAN TISSUE; INOTROPISM; MUSCLE FORCE; MUSCLE TONE; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

EID: 0030423420     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1996.tb00317.x     Document Type: Article

References (92)

1. Abe Y, Kitada Y, Narimatsu A, Tobe A. Improvement of postischemic contractile dysfunction of dog heart by MCI-154, a novel cardiotonic agent. Eur J Pharmacol 1991;192:279-285.
2. Allert JA, Adams HR. Inotropic and chronotropic profile of MCI-154: Comparison with isoproterenol and imazodan in guinea pig cardiac preparations. J Cardiovasc Pharmacol 1990;16:59-67.
3. Assmann I. Klinische Ergebnisse mit sog. Calcium-Sensitizern. Z Kardiol 1995;84:1050.
4. Beier N, Harting J, Jonas R, Klockow M, Lues I, Haeusler G. The novel cardiotonic agent EMD 53998 is a potent calcium sensitizer. J Cardiovasc Pharmacol 1991;18:17-27.
5. Beier N, Jonas R, Klockow M, et al. The two mechanisms of action of the racemic cardiotonic EMD 53998, Ca-sensitization and PDE-inhibition, reside in different enantiomers. J Mol Cell Cardiol (Suppl V) 1991; 23:S69.
6. 2+ as an inotropic mechanism. Circulation (Suppl III) 1986;73:III-85-III-98.
7. 2+ concentration in living cells. Prog Biophys Mol Biol 1982;40.1-114.
8. Bolli R. Myocardial "stunning" in man. Circulation 1992;86:1671-1691.
9. Bolli R, Hartley CJ, Rabinovitz RS. Clinical Relevance of Myocardial "Stunning." In: Opie LH, ed. Stunning, hibernation, and calcium in myocardial ischemia and reperfusion. Boston, Dordrecht, London: Kluwer Academic Publishers, 1992;3:56-82.
10. Bolli R, Zhu W-X, Myers ML, Hartley CJ, Roberts R. Beta-adrenergic stimulation reverses postischemic myocardial dysfunction without producing subsequent deterioration. Am J Cardiol 1985;56:964-968.
11. Böhm M, Morano I, Pieske B, et al. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 1991;68:689-701.
12. Braunwald E. Newer positive inotropic agents: Introduction. Circulation 1986;73:1-3.
13. Brunckhorst D, Van der Leyen H, Meyer W, Nigbur R, Schmidt Schumacher C, Scholz H Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 CI, milrinone, and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea pig heart. Naunyn Schmiedebergs Arch Pharmacol 1989;339:575-583.
14. Carrozza JP, Bentivegna LA, Williams CP, Kuntz RE, Grossmann W, Morgan JP. Decreased myofilament responsiveness in myocardial stunning follows transient calcium overload during ischemia and reperfusion. Circ Res 1992;71:1334-1340.
15. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. N Engl J Med 1986;314:349-358.
16. De Tombe PP, Burkhoff D, Hunter WC. Effects of calcium and EMD-53998 on oxygen consumption in isolated canine hearts. Circulation 1992;86.1945-1954.
17. De Tombe PP, Burkhoff D, Hunter WC. Comparison between the effects of 2-3 butanedione monoxime (BDM) and calcium chloride on myocardial oxygen consumption. J Mol Cell Cardiol 1992;24:783-797.
18. Dietrich DLL, van Leeuwen GR, Stienen GJM, Elzinga G. Stunning does not change the relation between calcium and force in skinned rat trabeculae. J Mol Cell Cardiol 1994;25:541-549.
19. Edes I, Papp GJ, Csanády M. The effects of a new calcium sensitizer, simendan, on intracellular protein phosphorylation. J Mol Cell Cardiol 1992;24:93.
20. Endoh M. The effects of various drugs on the myocardial inotropic response. Gen Pharmacol 1995;26:1-31.
21. 2+ mediated through α- and β-adrenoceptor. Circ Res 1988;62:247-265.
22. Endoh M, Hori M. Basic pharmacology and clinical application of new positive inotropic agents. Drugs Today 1993;29:29-56.
23. 2+ -sensitizers. Personal communication.
24. Farah AE, Alousi AA, Schwarz Jr RP. Positive inotropic agents. Annu Rev Pharmacol Toxicol 1984;24: 275-328.
25. 2+ transient in rat myocardium. J Mol Cell Cardiol 1991;23:325-331.
26. Gambassi G, Capogrossi MC, Klockow M, Lakatta EG. Enantiomeric dissection of the effects of the inotropic agent, EMD 53998, in single cardiac myocytes. Am J Physiol 1993,264:H728-H738.
27. Gambassi G, Solaro RJ, Spurgeon HA, et al. EMD 57033, a novel inotropic agent, reverses myofilament effects of butanedione monoxime (BDM). Circulation 1992;86:I-623.
28. Gao WD, Atar D, Backx PH, Marban E Relationship between intracellular calcium and contractile force in stunned myocardium. Circ Res 1995;76:1036-1048.
29. 2+ sensitivity in intact versus skinned rat ventricular muscle. Circ Res 1994;74:408-415.
30. 2+ -sensitizer EMD 57033 on isolated guinea pig cardiac muscle: Increase in isometric force with minor changes in energy expenditure. Pfluegers Arch (Suppl 1) 1991;419:R106.
31. Gross T, Lues I, Daut J. A new cardiotonic drug reduces the energy cost of active tension in cardiac muscle. J Mol Cell Cardiol 1993;25:239-244.
32. Guth BD, Schulz R, Heusch G. Time course and mechanisms of contractile dysfunction during acute myocardial ischemia. Circulation (Suppl IV) 1993;87:35-42.
33. Haikala H, Nissinen E, Etemadzadeh E, Lindén IB, Pohto P. Levosimendan increases calcium sensitivity without enhancing myosin ATPase activity and impairing relaxation. J Mol Cell Cardiol 1992;24:97-101.
34. Hasenfuss G. Neue Kardiotonika/Inodilatoren. Energetische Aspekte. Z Kardiol 1992;81:57-63.
35. Hasenfuss G, Holubarsch C, Heiss HW, et al. Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone. Circulation 1989;80.51-64.
36. Hasenfuss G, Holubarsch C, Heiss HW, Rattert B, Just H. Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside. Basic Res Cardiol (Suppl 1) 1989;84:225-233.
37. Hata K, Goto Y, Futaki S, et al. Mechanoenergetic effects of pimobendan in canine left ventricles. Comparison with dobutamine. Circulation 1992;86:1291-1301.
38. Hearse DJ. Stunning. A radical re-view Cardiovasc Drugs Ther 1991;5:853-876.
39. Herzig JW, Depersin H, Huber P, et al. Ca sensitivity of the myocardium as influenced by Ca sensitizing agents and in some models of heart failure. J Mol Cell Cardiol 1991;23:30.
40. 2+ sensitizing agents Z Kardiol 1992;81:49-55.
41. Heusch G, Schäfer S, Kröger K Recruitment of inotropic reserve in "stunned" myocardium by the cardiotonic agent AR-L 57. Basic Res Cardiol 1988;83.602-610
42. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975;56:978-985.
43. Hofmann PA, Miller WA, Moss RL. Altered calcium sensitivity of isometric tension in myocyte-sized preparations of porcine postischemic stunned myocardium. Circ Res 1993;72:50-56.
44. 2+ binding sites on cardiac troponin and their role in the regulation of adenosine triphosphatase. J Biol Chem 1980;255:11688-11693.
45. Holubarsch C, Hasenfuss G, Just H, Blanchard EM, Mulieri LA, Alpert NR. Modulation of myothermal economy in isometric force generation by positive inotropic interventions in the guinea pig myocardium. Cardioscience 1990;1:33-41.
46. Ito BR, Tate H, Kobayashi M, Schaper W. Reversibly injured, postischemic canine myocardium retains normal contractile reserve Circ Res 1987;61:834-846.
47. Katz AM. Energy requirements of contraction and relaxation: Implications for inotropic stimulation of the failing heart. Basic Res Cardiol (Suppl 1) 1989;84:47-53.
48. Katz AM, Hecht HH. The early "pump" failure of the ischemic heart. Am J Med 1969;47:497-502.
49. Kawabata Y, Endoh M. Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res 1993;72:579-606.
50. 2+ . Comparison with sulmazole and pimobendan. J Pharmacol Exp Ther 1991;257:812-819.
51. 2+ -transient as cardiotonic principles shown in cardiac myocytes. J Mol Cell Cardiol (Suppl V) 1991;23:S29.
52. 2+ sensitivity in normal and stunned myocardium of isolated rabbit hearts. Basic Res Cardiol 1994;89:549-562.
53. 2+ sensitivity of myofibrillar ATPase activity in skinned fibres from pig ventricles. Pfluegers Arch 1990;415:741-746.
54. 2+ transients underlie stunning? Circ Res 1990;66: 1268-1276.
55. Kusuoka H, Porterfield JK, Weisman HF, Weisfeldt ML, Marban E Pathophysiology and pathogenesis of stunned myocardium: Depressed Ca-activation of contraction as a consequence of reperfusion-induced cellular calcium overload in ferret hearts. J Clin Invest 1987;79:950-961.
56. Kusuoka H, Weisfeldt ML, Zweier JL, Jacobus WE, Marban E. Mechanism of early contractile failure during hypoxia in intact ferret heart: Evidence for modulation of maximal Ca-activated force by inorganic phosphate. Circ Res 1986;59:270-282.
57. Lamers JMJ, Duncker DJ, Bezstarosti K, McFalls EO, Sassen LMA, Verdouw PD. Increased activity of the sarcoplasmic reticular calcium pump in porcine stunned myocardium. Cardiovasc Res 1993;27:520-524.
58. Lee JA, Allen DG. Calcium sensitizers. Br Med J 1990;300:551-552.
59. Lee JA, Allen DG. EMD 53998 sensitizes the contractile proteins to calcium in the ferret ventricle muscle. Circ Res 1991;69:927-936.
60. Lee JA, Shah N, White J, Orchard CH. A novel thiadiazinone derivative fully reverses acidosis-induced depression of force in cardiac muscle by a calcium effect. Clin Sci 1993;84:141-144.
61. 2+-sensitizing agent. Pflügers Arch Eur J Physiol 1992;421:388-390.
62. Lues I. Calcium-Sensitisierung als neues Therapiekonzept: Tierexperimentelle Befunde. Z Kardiol 1995; 84:1050.
63. Lues I, Beier N, Jonas R, Klockow M, Haeusler G. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers. J Cardiovasc Pharmacol 1993,21:883-892.
64. Marban E, Koretsune Y, Corretti M, Chacko VP, Kusuoka H. Calcium and its role in myocardial cell injury during ischemia and reperfusion. Circulation (Suppl IV) 1989;80:IV-17-IV-22.
65. Miller DJ, Lamont C, O'Dowd JJ. Modulation of cardiac calcium sensitivity: A new approach to increasing the strength of the heart. In: Lee JA, Allen DG, eds Natural Calcium-Sensitizing Compounds of the Heart. New York: Oxford University Press, 1993:115-139.
66. Miller DJ, Steele DS. The 'calcium sensitising' effects of ORG30029 in saponin- or Triton-skinned rat cardiac muscle. Br J Pharmacol 1990;100:843-849.
67. Morgan JP. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. New Engl J Med 1991;325:625-632.
68. Mruck S, Rose H, Kammermeier H. Higher energetic efficiency of rat cardiomyocyte contraction upon positive inotropic intervention with a calcium sensitizer (EMD 57033) J Mol Cell Cardiol (Suppl 5) 1992;24:96.
69. Neumann J, Boknik P, Schmitz W, Scholz H, Zimmermann N. Comparison of the stereoselective effects of a thiadiazinone derivative on contractile parameters and protein phosphorylation in the mammalian ventricle. J Cardiovasc Pharmacol 1995;25:789-793.
70. 2+ transients and contractile properties by beta-adrenoceptor stimulation in ferret ventricular muscles. J Physiol 1990,423:221-240.
71. Packer M. Combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med 1989; 320.709-718
72. Pagel PS, Hettrick DA, Warltier DC. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency Basic Res Cardiol 1996 (in press).
73. Parrish MD, Payne A, Fixler DE. Global myocardial ischemia in the newborn, juvenile, and adult isolated isovolumic rabbit heart. Age-related differences in systolic function, diastolic stiffness, coronary resistance, myocardial oxygen consumption, and extracellular pH Circ Res 1987;61:609-615
74. 2+-Sensibilität der kontraktilen Proteine. Med Klin (Suppl) 1994;89:188.
75. Ravens U, Flüss M, Li Q, et al. Stereoselective calcium sensitizing but non-stereoselective electrophysiological actions of [+]-EMD 60263 and [-]-EMD 60264. Br J Pharmacol 1995 (in press).
76. Reiter M. Calcium mobilization and cardiac inotropic mechanisms. Pharmacol Rev 1988;40:189-217.
77. Rose H, Pöpping S, Mruck S, et al. Influence of inotropic interventions on efficiency of cardiomyocyte contraction. J Mol Cell Cardiol 1992;24:110.
78. Rüegg JC. Modulation of calcium sensitivity in cardiac muscle cells. Basic Res Cardiol (Suppl 2) 1985; 80:79-82.
79. Rüegg JC. Effects of new inotropic agents on calcium sensitivity of contractile proteins. Circulation 1986;73:III-78-III-84.
80. Rüegg JC. Dependence of cardiac contractility on myofibrillar calcium sensitivity. NIPS 1987;2:179-182.
81. Rüegg JC. The vertebrate heart: Modulation of calcium control. In: Rüegg JC, ed. Calcium in Muscle Contraction. 2nd ed. Berlin, Heidelberg, New York: Springer-Verlag, 1992;7:165-200.
82. Rüegg JC, Morano I. Calcium-sensitivity modulation of cardiac myofibrillar proteins. J Cardiovasc Pharmacol (Suppl 3) 1989;14:S20-S23.
83. Schelling P, Becker KH, Lues I, et al. In vivo characterization of the cardiotonic action of EMD 57033, a novel drug that increases left ventricular contractility via sensitization of myofibrils to calcium. J Mol Cell Cardiol (Suppl 5) 1991;23:S69.
84. Simnett SJ, Lipscomb S, Ashley CC, Mulligan IP. The effect of EMD 57033, a novel cardiotonic agent, on the relaxation of skinned cardiac and skeletal muscle produced by photolysis of diazo-2, a caged calcium chelator. Pfluegers Arch 1993;425:175-177.
85. 2+ sensitization predominantly enhances function and mechanical efficiency of stunned myocardium. Circulation 1994;90: 959-969.
86. 2+, pH and the regulation of cardiac myofilament force and ATPase activity. Mol Cell Biochem 1989;89:164-167.
87. Solaro RJ, Gambassi G, Warshaw DM, et al. Stereoseiective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res 1993;73:981-990.
88. 2+ sensitivity of chemically skinned rat heart. J Physiol 1990;422:499-511.
89. 2+ sensitization and phosphodiesterase III inhibitory effects in guinea pig myocardium. Circ Res 1992;70:1081-1090.
90. 2+ in isolated ferret cardiac muscle. Circ Res 1993;73:61-70.
91. Wijns W, Serruys PW, Slager CJ, et al. Effect of coronary occlusion during percutaneous transluminal angioplasty in humans on left ventricular chamber stiffness and regional diastolic pressure-radius relations. J Am Coll Cardiol 1986;7:455-463.
92. Winegrad S. Regulation of cardiac contractile proteins - Correlation between physiology and biochemistry. Circ Res 1984;55:565-574.